Overview

Price chart · mood · technical indicators

SNSE

Sensei Biotherapeutics Incstock Healthcare

Biotechnology

$26.70235.93%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$5.25$36.76

Current: $26.70

Market Comparison

vs Healthcare Sector & Biotechnology Industry

SNSE

+235.93%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-16.720.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$36.2MMicro cap

Wall Street coverage

$50.00median target· current $36.80 (+35.9%)2 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 1.95
P/S (TTM): —
EV/EBITDA: 1.36

Profitability & growth

ROE (TTM): -74.0%
Operating margin: 0.0%
Revenue growth YoY: 0.0%
Dividend yield: —
Beta: -0.18

Last earnings

Dec 31, 2025 · Estimate $-4.81 · Reported $-3.74

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Sensei Biotherapeutics Inc

Company profile

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, is dedicated to the discovery and development of therapies with an initial focus on cancer treatments. The company is headquartered in Rockville, Maryland.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 1405 RESEARCH BOULEVARD, ROCKVILLE, MD
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$36.2M

Shares outstanding$1.3M

52W high$36.76

52W low$5.26

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

SNSE

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

[144] Sensei Biotherapeutics, Inc. SEC Filing

Sensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00

[ARS] Sensei Biotherapeutics, Inc. SEC Filing

Sensei Biotherapeutics (NASDAQ: SNSE) registers 24.87M resale shares

Faeth-focused recapitalization at Sensei (NASDAQ: SNSE) reshapes ownership and adds $200M

Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target By Investing.com

Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target

Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target

Sensei Biotherapeutics Announces Leadership and Board Transitions

Sensei Biotherapeutics: If Proposals Are Approved, COO Anand Parikh Is Expected to Become CEO

Leadership and board overhaul outlined by Sensei Biotherapeutics (NASDAQ: SNSE)

Faeth deal shifts control; Sensei Biotherapeutics (NASDAQ: SNSE) seeks shareholder approvals

Sensei Biotherapeutics (SNSE) details Faeth acquisition, PIPE and going-concern warning

Director at Sensei Biotherapeutics (SNSE) receives 23,100 stock options

Sensei Biotherapeutics (SNSE) grants PFO 80,000 stock options

Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Sidley Represents Sensei Biotherapeutics in Acquisition of Faeth Therapeutics

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

About Sensei Biotherapeutics Inc

Classification

Company profile

SNSE

Market Comparison

SNSE Market Analysis

Overview

SNSE

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

[144] Sensei Biotherapeutics, Inc. SEC Filing

Sensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00

[ARS] Sensei Biotherapeutics, Inc. SEC Filing

Sensei Biotherapeutics (NASDAQ: SNSE) registers 24.87M resale shares

Faeth-focused recapitalization at Sensei (NASDAQ: SNSE) reshapes ownership and adds $200M

Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target By Investing.com

Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target

Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target

Sensei Biotherapeutics Announces Leadership and Board Transitions

Sensei Biotherapeutics: If Proposals Are Approved, COO Anand Parikh Is Expected to Become CEO

Leadership and board overhaul outlined by Sensei Biotherapeutics (NASDAQ: SNSE)

Faeth deal shifts control; Sensei Biotherapeutics (NASDAQ: SNSE) seeks shareholder approvals

Sensei Biotherapeutics (SNSE) details Faeth acquisition, PIPE and going-concern warning

Director at Sensei Biotherapeutics (SNSE) receives 23,100 stock options

Sensei Biotherapeutics (SNSE) grants PFO 80,000 stock options

Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Sidley Represents Sensei Biotherapeutics in Acquisition of Faeth Therapeutics

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

About Sensei Biotherapeutics Inc

Classification

Company profile

SNSE

Market Comparison